BACKGROUND: Data on 25-hydroxyvitamin D (25-OH D) status among survivors of childhood cancer are limited. Our aim was to determine the prevalence of and risk factors for 25-OH D insufficiency in a large, diverse population of cancer survivors being followed in a childhood cancer survivor clinic. PROCEDURE: Retrospective chart review in survivors seen for routine long-term follow-up, who underwent routine screening blood studies including 25-OH D levels. Vitamin D insufficiency was defined as 25-OH D <20 ng/ml. RESULTS: Four hundred eighty-four subjects (234 males) were evaluable for this analysis. Median age at 25-OH D testing was 12.3 years (2.05-36.4) and median age at cancer diagnosis was 3.9 years (0-18). Diagnoses included brain tumors (23.6%), neuroblastoma (21%), and leukemia (17.6%). Mean 25-OH D level was 25.2 ng/ml (SD = 10.37); 29% of subjects were 25-OH D insufficient. In univariate analysis, race, pubertal status, and age at cancer diagnosis were associated with 25-OH D insufficiency (P < 0.05). In multivariate analysis, a model including race and pubertal status provided a good fit for the data. CONCLUSIONS: The prevalence of 25-OH D insufficiency in these cancer survivors was high but similar to what has been described in the general population. No cancer specific variables were associated with 25-OH D insufficiency. Since cancer survivors are at a higher risk for subsequent malignancies, cardiovascular disease, and low bone mineral density, all of which may be affected by 25-OH D levels, interventions to improve 25-OH D status in this vulnerable population are needed.
BACKGROUND: Data on 25-hydroxyvitamin D (25-OH D) status among survivors of childhood cancer are limited. Our aim was to determine the prevalence of and risk factors for 25-OH Dinsufficiency in a large, diverse population of cancer survivors being followed in a childhood cancer survivor clinic. PROCEDURE: Retrospective chart review in survivors seen for routine long-term follow-up, who underwent routine screening blood studies including 25-OH D levels. Vitamin Dinsufficiency was defined as 25-OH D <20 ng/ml. RESULTS: Four hundred eighty-four subjects (234 males) were evaluable for this analysis. Median age at 25-OH D testing was 12.3 years (2.05-36.4) and median age at cancer diagnosis was 3.9 years (0-18). Diagnoses included brain tumors (23.6%), neuroblastoma (21%), and leukemia (17.6%). Mean 25-OH D level was 25.2 ng/ml (SD = 10.37); 29% of subjects were 25-OH D insufficient. In univariate analysis, race, pubertal status, and age at cancer diagnosis were associated with 25-OH Dinsufficiency (P < 0.05). In multivariate analysis, a model including race and pubertal status provided a good fit for the data. CONCLUSIONS: The prevalence of 25-OH Dinsufficiency in these cancer survivors was high but similar to what has been described in the general population. No cancer specific variables were associated with 25-OH Dinsufficiency. Since cancer survivors are at a higher risk for subsequent malignancies, cardiovascular disease, and low bone mineral density, all of which may be affected by 25-OH D levels, interventions to improve 25-OH D status in this vulnerable population are needed.
Authors: Amy L Skversky; Juhi Kumar; Matthew K Abramowitz; Frederick J Kaskel; Michal L Melamed Journal: J Clin Endocrinol Metab Date: 2011-09-28 Impact factor: 5.958
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Pediatrics Date: 2002-01 Impact factor: 7.124
Authors: Shanna Nesby-O'Dell; Kelley S Scanlon; Mary E Cogswell; Cathleen Gillespie; Bruce W Hollis; Anne C Looker; Chris Allen; Cindy Doughertly; Elaine W Gunter; Barbara A Bowman Journal: Am J Clin Nutr Date: 2002-07 Impact factor: 7.045
Authors: A Catharine Ross; JoAnn E Manson; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; Susan T Mayne; Clifford J Rosen; Sue A Shapses Journal: J Clin Endocrinol Metab Date: 2010-11-29 Impact factor: 5.958
Authors: K Robien; L G Strayer; N Majhail; D Lazovich; K S Baker; A R Smith; D A Mulrooney; L J Burns Journal: Bone Marrow Transplant Date: 2011-01-17 Impact factor: 5.483
Authors: Lori J Bechard; Catherine Gordon; Henry A Feldman; Robert Venick; Kathleen Gura; Eva C Guinan; Christopher Duggan Journal: Pediatr Blood Cancer Date: 2015-01-28 Impact factor: 3.167
Authors: Seth E Karol; Leonard A Mattano; Wenjian Yang; Kelly W Maloney; Colton Smith; ChengCheng Liu; Laura B Ramsey; Christian A Fernandez; Tamara Y Chang; Geoffrey Neale; Cheng Cheng; Elaine Mardis; Robert Fulton; Paul Scheet; F Anthony San Lucas; Eric C Larsen; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Meenakshi Devidas; Mary V Relling Journal: Blood Date: 2015-11-20 Impact factor: 22.113
Authors: Paula Aristizabal; Michael Sherer; Bianca P Perdomo; Esteban Castelao; Courtney D Thornburg; James Proudfoot; Elizabeth Jacobs; Ron S Newfield; Peter Zage; William Roberts; Maria Elena Martinez Journal: Pediatr Hematol Oncol Date: 2020-03-10 Impact factor: 1.969
Authors: Susan R Rose; Vincent E Horne; Jonathan Howell; Sarah A Lawson; Meilan M Rutter; Gylynthia E Trotman; Sarah D Corathers Journal: Nat Rev Endocrinol Date: 2016-04-01 Impact factor: 43.330